Skip to content


    DEA Class; Rx

    Common Brand Names; Novantrone

    • Antineoplastics, Anthracenedione; 
    • Multiple Sclerosis Treatments

    Anthracenedione; structurally similar to the anthracyclines; causes less cardiotoxicity than anthracylines; not a vesicant; used in hematologic malignancies and prostate cancer; also effective in relapsing-remitting and secondary progressive MS.

    Indicated for the treatment of acute myelogenous leukemia (AML).

    For the palliative treatment of severe pain related to advanced hormone-refractory prostate cancer in combination with corticosteroids.

    For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis to reduce neurologic disability and/or frequency of clinical relapses.

    For the treatment of relapsed or refractory acute lymphocytic leukemia (ALL) in combination with ifosfamide and etoposide.


    • Nausea (55%)
    • Upper respiratory infection (51%)
    • Alopecia (38%
    • Urinary tract infection (29%)
    • Amenorrhea (28%)
    • Diarrhea (25%)
    • Stomatitis (15%)
    • Constipation (14%)
    • Headache (6%)
    • Back pain (6%)

    Not indicated for primary progressive MS

    Risk of cardiotoxicity & secondary AML

    Avoid pregnancy

    If extravasation occurs, stop immediately & restart in another vein

    Hepatic impairment

    Pregnancy Category: D

    Lactation: excreted in breast milk, do not nurse


    The maximum cumulative lifetime dose of mitoxantrone is 140 mg/m2 IV.


    injectable solution

    • 2mg/mL